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1. Introduction 
Chronic obstructive pulmonary disease (COPD) that presents a growing cause for mortality 
worldwide [1, 2] is characterized by chronic bronchitis, obstructive bronchiolitis and 
emphysema. The most important etiologic factor is cigarette smoking, but occupational and 
environmental dusts as well as genetic factors contribute to COPD developing. The 
exposure to these noxious inhaled agents lead to abnormal pathogenic reactions like a 
permanent airway inflammation, imbalance between proteinases and antiproteinases, 
impairment of elastin repair and increased oxidative stress with subsequent lung 
parenchyma destruction [3]. The progressive permanent enlargement of airspaces distal to 
terminal bronchioles results in a decrease in lung elastic recoil, air trapping and 
hyperinflation, thus leading to airflow limitation and increased residual volume. These 
alterations of respiratory mechanics cause the symptoms of dyspnoea, limited exercise 
capacitiy and reduced quality of life. Therapeutic recommendations for COPD consisting of 
bronchodilators, glucocorticosteroids, long term oxygen therapy and rehabilitation are 
common insufficient in advanced COPD [4]. Therefore, surgical treatments like Lung 
Volume Reduction Surgery (LVRS) and lung transplantation should be considered in 
advanced disease. The resection of emphysematous lung tissue results in improvement of 
lung elastic recoil with subsequent increased expiratory flow. Furthermore, the reduction of 
hyperinflation allows the diaphragm to function more effectively and increases the global 
inspiratory muscle strength [5]. 
Already in the 1950s, the first lung volume reduction surgery has been performed to achieve 
lung volume reduction with subsequent improvement of respiratory mechanics leading to 
decreased breathlessness on exertion and increased exercise capacity. Although a 
physiological improvement could be observed, the surgical treatment did not attract 
attention due to high perioperative mortality [6]. Just in the 1990s the surgical treatment was 
reintroduced and the positive results have been confirmed in several trials [7-10]. The most 
known trial related to LVRS is the multicenter “National Emphysema Treatment Trial” 
(NETT) [10] comparing the surgical treatment to standard medical care in 1.218 patients 
with severe emphysema. The results of NETT showed that patients with predominantly 
upper lobe emphysema experienced significant improvement in clinical outcome 
measurements. However, the 90-day mortality rate in the surgery group was 7.9% and thus 
significant higher than in the medical-therapy group. Particularly, in patients with non 
upper lobe predominant emphysema and poor lung function, a high mortality could be 
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observed. Therefore, different bronchoscopic approaches have been developed imitating the 
LVRS but with less morbidity and mortality.  
Until now, there are various techniques of Endoscopic Lung VolumeReduction (ELVR) 
extending the therapeutic strategies in patients withsevere emphysema. In general, 
reversible blocking techniques and irreversible, non-blocking techniques can be 
distinguished. The application of these different techniques is dependent on the emphysema 
distribution and degree of collateral ventilation. Therefore, an accurate patient selection has 
great importance. 
2. Reversible, blocking techniques 
The first and most known method of endoscopic lung volume reduction is the implantation 
of valves in targeted most destroyed lung compartments in patients with heterogeneous 
emphysema [11]. These blocking devices allow the air to be expelled during expiration but 
prevent the air entering the target lobe during inspiration and so facilitating atelectasis to 
achieve lung volume reduction. Two different valves are available: endobronchial valves 
(EBV, Zephyr ®, Pulmonx, Inc., Palo Alto, Calif., USA) and intrabronchial valves (IBV, 
Spiration®, Olympus Medical Co., Tokio, Japan).  
2.1 Implantation technique 
The endobronchial (figure 1) and intrabronchial valves (figure 2) only differentiate in shape, 
but the implantation technique and their functional principle is very similar. The 
endobronchial valves consist of a cylindrical nitinol framework, whereas the intrabonchial 
valves have got an umbrella shaped nitinol skeleton. Both valves are covered by a silicone 
membrane. Endobronchial valves are available in two different sizes, intrabronchial valves 
in three different sizes. Prior to valve implantation, the diameter of the bronchus that is 
considered to be blocked by the valves is estimated by using the measurement wings of the 
delivery system or a special balloon catheter. Afterwards, the appropriately sized valves are 
preloaded in a delivery catheter that can be introduced through a 2.8 mm or larger working 
channel of a standard flexible bronchoscope. The catheter is placed in the airway of the 
target lobe and by retracting the sheath, the valve can be deployed easily that expanded 
against the bronchial wall. The procedure can be performed under general anesthesia as 
well as under conscious sedation and takes generally 10 to 30 minutes depending on the 
number of valves that are placed. 
2.2 Endobronchial valves (EBV) 
The first published trials related to endoscopic lung volume reduction by valves were about 
the implantation of EBV in patients with severe heterogeneous emphysema by Toma et al. 
and Snell et al. in 2003 [12; 13]. Since then, several series have been published [14; 15]. The 
biggest and most noted trail however is the “Endobronchial Valve for Emphysema 
Palliation Trial” (VENT) that has been published by Sciurba et al. in 2007 [16]. In this 
prospective trial, 321 patients with severe emphysema were randomly assigned in a 2:1 ratio 
to receive endobronchial valve treatment or standard medical care. 6 months following the 
treatment, the results referring to the lung function test revealed a mean between group-
difference of 6.8% in FEV1. 
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Fig. 1. Endobronchial valve. 
 
Fig. 2. Intrabronchial valve. 
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Furthermore, a mean between-group difference of 5.8% in the 6-minute-walk distance could be 
detected. Among the patients who received EBV, there was a greater reduction in the lung 
volume of the target lobe measured by high-resolution computed tomography (HRCT). At 12 
months, the complication rate was 10.3% in the EBV group versus 4.2% in the control group. 
Some predictive characteristics were observed in sub analysis of this study. The beneficial 
effects were greatest in patients with presence of high heterogeneity of their emphysema 
distribution and an accurate lobar exclusion by the valves. Furthermore, interlobar fissure 
integrity that was analyzed as a surrogate for collateral ventilation (CV) in the computed 
tomography has also been observed as an independent predictor of treatment response. 
Therefore it is thought that CV is one of the most relevant factors responsible for valve 
therapy failure. Nowadays, there are two different options to predict the CV and thus the 
success of valve treatment. On the one hand, fissure integrity can be assessed in the HRCT, 
on the other hand, a catheter-based endobronchial approach providing quantitatively 
measurement of collateral resistance has been proposed (figure 3). In one double-blind 
prospective study in 2010 evaluating the safety and feasibility of this catheter-based system 
25 patients with heterogeneous emphysema underwent the endobronchial determination of 
collateral resistance by using the catheter-based system followed by an EBV treatment [17]. 
In all patients, the resistance measurement was safely and successfully achieved. A 
correlation of the measurements with the event of atelectasis after ELVR was found in 90% 
of the analyzable cases. In a following multicenter study covering patients with severe 
heterogeneous upper lobe or lower lobe predominant emphysema, the accuracy of this 
catheter-based system in correctly predicting the target lobe volume reduction was 
evaluated [18]. Following the CV measurement by using the catheter-based system a 
complete occlusion of the target lobe by EBV was performed. The target lobe volume 
reduction after the valve implantation was assessed by HRCT 30 days following the 
intervention. Out of 80 patients, CV assessment prospectively showed a low CV in 51 
patients and a high CV in 29 patients. The accuracy of the catheter-based system in correctly 
predicting the target lobe volume reduction was found to be 75%. Therefore, this 
quantitatively measurement of collateral ventilation predicts of whether endoscopic lung 
volume reduction would be successfully or not. 
2.3 Intrabronchial valves (IBV) 
There are also several published trials confirming the efficacy of the treatment with 
intrabronchial valves in patients with heterogeneous emphysema. In most of these studies a 
bilateral incomplete occlusion of both lobes in patients with upper lobe predominant 
emphysema was performed to minimize the risk of pneumothorax. The results showed an 
improvement in health-related quality of life and regional lung volume changes measured 
by quantitative and qualitative analysis of HRCT [19; 20; 21]. However, in all these studies 
no significant change in lung function test or 6-minute-walk test could be observed. 
Therefore, it is thought, that bilateral partial closure leads to redistribution of ventilation but 
avoid atelectasis with subsequent absence of improvement of these objective clinical 
outcome measures. To evaluate this hypothesis, a randomized prospective study comparing 
unilateral complete versus bilateral incomplete endoscopic lung volume reduction by IBV 
implantation in 20 patients with severe upper lobe predominant emphysema was performed 
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[22]. The results demonstrated a greater benefit in patients receiving the unilateral 
endoscopic lung volume reduction with complete occlusion of one lobe. Significant 
differences were evaluated in FEV1 (+32.5% vs. +2.5%) as well as in the 6-minute-walk test 
(+43m vs. -19m). In conclusion, unilateral treatment with complete occlusion appears 
superior to bilateral incomplete treatment but with higher risk of pneumothorax. 
 
Fig. 3. Catheter-based measurement of collateral ventilation. At the tip of the catheter, there 
is a balloon, that is be inflated within the airway to isolate the target lobe. The air is directed 
through the catheter to the console for measurement of air flow and air pressure. 
3. Irreversible, non-blocking techniques 
Besides the blocking devices, there are various non-blocking techniques for bronchoscopic 
emphysema therapy. Implantation of lung volume reduction coils, polymeric lung volume 
reduction, bronchoscopic thermal vapour ablation and creation of airway bypasses can be 
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distinguished. These techniques seem to be independent of collateral ventilation, however 
these methods are irreversible. 
 
Fig. 4. Chest x-ray following the implantation of lung volume reduction coils in the right 
upper lobe. In courtesy of Prof. Dr. med. CP Heussel, Thoraxklinik Heidelberg. 
3.1 Lung Volume Reduction Coils (LVRC) 
One of these non-blocking endoscopic techniques is the implantation of lung volume 
reduction coils (LVRC, PneumRx, Inc., Mountain View, Calif., USA). These coils consisting 
of a nitinol wire have got a preformed shape that results in parenchymal compression and 
thus achieving a lung volume reduction. For implantation, the airway is identified 
bronchoscopically. Afterwards a low stiffness guidewire is advanced into the airway under 
fluoroscopic guidance with a distance of 15 mm between the distal end of the guidewire and 
the pleura. Next, a catheter is passed over the guidewire. Then the guidewire is removed 
and a straightened LVRC is introduced. As the catheter is pulled back, the coil assumes its 
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preformed shape leading to parenchymal compression. Figure 4 shows a chest x-ray 
following implantation of coils in the right upper lobe. In a pilot study using coils in 
heterogeneous as well as in homogeneous emphysema, the patients with predominant 
heterogeneous disease appeared to show more substantial improvements in pulmonary 
function, lung volumes, 6 minute walk test and quality of life measures than patients with 
homogeneous disease [23]. According to these results, a study investigating the efficacy of 
LVRC treatment in 16 patients with only severe heterogeneous emphysema was performed 
[24]. 12 patients were treated bilaterally, 4 patients underwent treatment in one lobe. A 
median of 10 coils per lobe were placed. LVRC treatment in all patients resulted in 
significant improvements in pulmonary function, exercise capacity and quality of life, with 
an acceptable safety. 
3.2 Polymeric Lung Volume Reduction (PLVR) 
Polymeric lung volume reduction (PLVR, Aeris therapeutics, Inc. Woburn, Mass., USA) 
consists of administration of a foam sealant in the destroyed lung compartment resulting in 
local inflammatory reaction. This inflammation leads to fibrosis and scarring with 
subsequent lung volume reduction (figure 5a and 5b). PLVR can be offered to patients with 
heterogeneous disease, but also patients with homogeneous disease experience 
improvement after PLVR. However, further trials evaluating the efficacy of PLVR in 
patients with severe homogeneous emphysema are needed. 
The sealant is administered via a special single lumen catheter that is inserted through the 
working channel of a standard flexible bronchoscope until its tip extends approximately 4 
cm from the tip of the scope. During the administration of the sealant, the bronchoscope is 
maintained in wedge position preventing backflow of the sealant at the airway subsegment. 
The injection time of the sealant that is prepared in a syringe takes about 10-20 seconds. The 
bronchoscope should be maintained in wedge position for one minute following delivery to 
allow complete in situ polymerization. Afterwards, the bronchoscope is repositioned at the 
next subsegment and the procedure is repeated [25]. 
The first studies related to PLVR showed encouraging results with beneficial effects in 
selected patients with heterogeneous emphysema [26; 27] as well as with homogeneous 
emphysema [28]. Furthermore, a multicenter dose-ranging study revealed, that patients who 
received high dose treatment with 20 ml per subsegment experienced greater improvement 
in clinical outcomes than patients with a low dose treatment with 10 ml per subsegment 
[27]. In these trials, biological reagents were instillated to initiate an inflammatory reaction 
and a collapse of targeted lung portions, but it then was replaced by synthetic AeriSeal foam 
that allows a simpler production without blood products.  
In one recently published multicenter trial, 25 patients with severe upper lobe predominant 
emphysema underwent PLVR by using AeriSeal foam [29]. All patients tolerated the 
treatment without significant adverse events. However, a flu-like reaction following the 
procedure could be detected in all patients. 24 weeks after the PLVR, physiological and 
clinical benefits were observed. Furthermore, efficacy responses were better among the 
patients with COPD GOLD (Global Initiative for Chronic Obstructive Lung Disease) stage 
III than among patients with COPD GOLD stage IV. 
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(a) 
 
(b) 
Fig. 5. Computed tomography acquired prior to polymeric lung volume reduction (a) in the 
left upper lobe and matched CT scan (b) taken 6 months following the treatment. The shift 
of the interlobar fissure shows the target lobe volume reduction. In courtesy of Prof. Dr. 
med. CP Heussel, Thoraxklinik Heidelberg. 
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3.3 Bronchoscopic Thermal Vapor Ablation (BTVA) 
Bronchoscopic thermal vapor ablation (BTVA, Uptake Medical, Seattle, Wash., USA) is an 
alternative method that is very similar to PLVR. This technique consists of a vapor generator 
and a special InterVapor catheter used to deliver heated water vapor bronchoscopically to 
the most destroyed lung regions. The vapor induces an inflammatory reaction with 
subsequent fibrosis and scarring leading to lung volume reduction (figure 6a and 6b).  
 
(a) 
 
(b) 
Fig. 6. Computed tomography taken prior to bronchoscopic thermal vapor ablation (a) in the 
right upper lobe. 6 months following the treatment a lobar volume reduction can be 
observed (b). In courtesy of Prof. Dr. med. CP Heussel, Thoraxklinik Heidelberg. 
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After identifying the target airway bronchoscopically, the InterVapor catheter is introduced 
through the working channel of the flexible bronchoscope. At the tip of the catheter there is 
a balloon that can be inflated within the airway so that the target lung region is isolated. 
Next, a predetermined dose of 125° C heated water vapor is delivered via the special 
InterVapor catheter. 
In a 2009 reported study, 11 patients with heterogeneous emphysema treated by unilateral 
BTVA confirmed the feasibility and an acceptable safety profile [30]. Furthermore, an 
improvement of health-related quality of life could be observed. A recently published 
multinational single arm study evaluated the efficacy of the bronchoscopic thermal vapor 
ablation in 44 patients with upper lobe predominant emphysema. 24 patients received 
BTVA in the right upper lobe, 20 patients were treated in the left upper lobe in a single 
procedure with a target vapor dose of 10 cal/g. During the procedure, no adverse events 
could be observed. The most common adverse events following the treatment were COPD 
exacerbations, pneumonia and haemoptysis. 6 months following the treatment, efficacy data 
showed a 48% reduction of treated lobar volume assessed by HRCT measurement. 
Furthermore, the patients experienced significant improvement in lung function, exercise 
capacity and health-related quality of life [31].  
3.4 Airway bypass 
The creation of extra-anatomic passageways through the normal bronchial wall allowing the 
trapped air to escape presents a method of endoscopic lung volume reduction in patients with 
severe homogeneous emphysema (EASE, Broncus Technologies, Inc. Mountain View, USA).  
The procedure is performed by using a standard flexible bronchoscope. After identifying the 
appropriate airway, a Doppler probe is used to confirm the absence of vessels behind the 
airway wall. Afterwards, the wall is punctured by a transbronchial needle. A balloon 
catheter is advanced into this hole and the balloon is inflated to enlarge the hole. After 
repeated confirmation of absence of vessels, a drug-eluting stent (DES) is placed to keep the 
bypass open over time. The trapped air can escape by bypassing the small airways leading 
to a lung volume reduction. 
In one large prospective, sham-controlled study - EASE trial (Exhale Airway Stents for 
Emphysema) - 315 patients with severe homogeneous emphysema were subdivided into 
two groups [32]: only 208 patients out of the 315 patients received the airway bypasses. 
Immediately post procedure, reductions in lung volume could be evaluated demonstrating 
proof of concept for airway bypass. However, for the overall group, the initial benefit 
decreases by 6 months so that at least no sustainable benefit could be recorded with airway 
bypass in the patients with homogeneous emphysema. The most probable cause for loss of 
initial benefit is stent occlusion by mucus. Therefore, improvement of durability is required 
before airway bypasses could be recommend as beneficial therapy.  
4. Patient selection 
An accurate patient selection is the most important and most difficult issue in the area of 
endoscopic lung volume reduction. The various approaches require different conditions that 
must be fulfilled to achieve beneficial outcome. Therefore a treatment algorithm is necessary 
for identifying the best candidates for the different techniques of endoscopic lung volume 
reduction. 
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Patients with severe emphysema have to undergo a screening basic examination 
programme including lung function testing (spirometry, bodyplethysmography, diffusing 
capacity measurements), blood gases and exercise tests (6-minute-walk test). 
Electrocardiogramm, echocardiogram, chest x-ray as well as laboratory testing provide to 
evaluate patient´s clinical status prior to bronchoscopic intervention. To determine the 
emphysema distribution as well as fissure integrity, high resolution computed tomography 
scan at full inspiration and perfusion scan are necessary. Different visual scoring systems 
e.g. YACTA®, Pulmo® or Volume® can be used for detailed quantitative emphysema 
analysis. As alternative method to fissure analysis by HRCT, the catheter-based 
measurement can be performed to evaluate the degree of collateral ventilation. 
 
Fig. 7. Patient selection and therapy algorithm. 
According to the VENT, following inclusion criteria should be fulfilled: forced expiratory 
volume in 1 s (FEV1) < 45%, total lung capacity (TLC) > 100%, residual volume (RV) > 150 %, 
a partial pressure of arterial carbon dioxide of 50 mm Hg or less, a partial pressure of 
arterial oxygen of at least 45 mm Hg (without oxygen therapy), a 6-minute-walk distance of 
> 140 m. Greatest beneficial effects can be observed in patients with a severe hyperinflation 
with a RV > 200% and a high RV/TLC. Depending on the emphysema distribution and the 
fissure integrity, the method of endoscopic lung volume reduction is chosen (see figure 1). 
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5. Complications 
5.1 Valve Implantation 
The most common adverse event following valve implantation is pneumonia distal the valves 
despite the valves allow secretion to pass. The VENT revealed a pneumonia rate of 4.2% [16]. 
In 1/3 of these cases, valve removal was necessary for recovery. In very rare cases, 
development of bronchiectasis can be observed distal the valves requiring valve removal. 
Another frequent risk is pneumothorax after valve treatment. Therefore, pneumothorax must 
be ruled out by chest x-ray 2 hours and 24 h following the intervention. Pneumothorax occurs 
particularly in patients who experience a great improvement in clinical outcome following 
valve placement due to a rapid atelectasis. Chest tube drainage is required in some patients 
with lung collapse. In case of persistent fistula, the removal of one of the implanted valves 
provides lung expanding and thus sealing fistula. Surgical intervention is only needed to treat 
fistula that remains persistent despite of adequate chest tube drainage and valve removal. 
Development of granulation tissue formation that is often associated with bleeding 
complication is another side effect related to valves due to the pressure of the valves on the 
mucosa. Cryotherapy is recommended for the treatment of severe granulation tissue 
formation. New or worsening hypercapnia is another adverse event. Therefore, repeated blood 
gas analysis following the valve implantation is required. Only in few cases non-invasive 
ventilation and/or valve removal is necessary. COPD exacerbation, mild haemoptysis, chest 
pain and valve migration are other anticipated complications to valve treatment.  
5.2 Coil Implantation 
Side effects rated as possibly related to either the procedure or the device are haemoptysis, 
dyspnoea, cough, COPD exacerbations, peumonia and chest pain. Pneumothorax can also 
occur following coil implantation. To minimize risk of pneumothorax, a distance of at least 
15 mm to pleura should be kept. 
5.3 Polymeric Lung Volume Reduction and Bronchoscopic Thermal Vapor Ablation 
The effect of PLVR and BTVA is based on an inflammatory reaction that results in fibrosis, 
scarring and shrinking. Due to this inflammation, the majority of the patients experience a 
“flu-like” reaction with dyspnoea, transient fever, pleuritic chest pain, leucocytosis, elevated 
C-reactive protein and infiltration in chest x-ray. This inflammatory response is self-limiting 
and resolves within 24-96 h with supportive care. Especially, systemic application of 
glucocorticosteroids is useful to diminish the symptoms following PLVR. Furthermore, a 7-
day course of antibiotic prophylaxis for one week is required in each patient. Other adverse 
effects following PLVR and BTVA include COPD exacerbation, pneumonia, bronchitis or 
haemoptysis. 
6. Conclusion 
Endoscopic lung volume reduction presents an encouraging therapy modality for patients 
with advanced emphysema. However, efficacy depends strictly on patient selection 
requiring an appropriate diagnostic and treatment algorithm for identifying the best 
candidates for each of the various ELVR techniques. Complete lobar occlusion by valve 
implantation provides an effective option for patients with severe heterogeneous upper lobe 
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or lower lobe predominant emphysema and low collateral ventilation. Irreversible, non-
blocking techniques that seem to be independent of collateral ventilation are minimally 
invasive endoscopic approaches for patients with upper lobe predominant emphysema. 
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Chronic Obstructive pulmonary disease (COPD) is an important cause of morbidity and mortality world-wide.
The most common cause is chronic cigarette smoke inhalation which results in a chronic progressive
debilitating lung disease with systemic involvement. COPD poses considerable challenges to health care
resources, both in the chronic phase and as a result of acute exacerbations which can often require hospital
admission. At the current time it is vital that scientific resources are channeled towards understanding the
pathogenesis and natural history of the disease, to direct new treatment strategies for rigorous evaluation.
This book encompasses some emerging concepts and new treatment modalities which hopefully will lead to
better outcomes for this devastating disease.
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